DE60127421T8 - Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen - Google Patents

Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen Download PDF

Info

Publication number
DE60127421T8
DE60127421T8 DE60127421T DE60127421T DE60127421T8 DE 60127421 T8 DE60127421 T8 DE 60127421T8 DE 60127421 T DE60127421 T DE 60127421T DE 60127421 T DE60127421 T DE 60127421T DE 60127421 T8 DE60127421 T8 DE 60127421T8
Authority
DE
Germany
Prior art keywords
vaccines
haemophilus influenzae
lipopolysaccharide
haemophilus
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60127421T
Other languages
English (en)
Other versions
DE60127421D1 (de
DE60127421T2 (de
Inventor
James C. Ottawa RICHARDS
Andrew Gloucester COX
Richard Moxon
Derek Institute of HOOD
Elke K. H. Schweda
Martin Mansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
University of Oxford
SCHWEDA ELKE
Original Assignee
National Research Council of Canada
University of Oxford
SCHWEDA ELKE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada, University of Oxford, SCHWEDA ELKE filed Critical National Research Council of Canada
Publication of DE60127421D1 publication Critical patent/DE60127421D1/de
Publication of DE60127421T2 publication Critical patent/DE60127421T2/de
Application granted granted Critical
Publication of DE60127421T8 publication Critical patent/DE60127421T8/de
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60127421T 2000-08-25 2001-08-27 Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen Expired - Fee Related DE60127421T8 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22785000P 2000-08-25 2000-08-25
US227850P 2000-08-25
PCT/CA2001/001225 WO2002016440A2 (en) 2000-08-25 2001-08-27 Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections

Publications (3)

Publication Number Publication Date
DE60127421D1 DE60127421D1 (de) 2007-05-03
DE60127421T2 DE60127421T2 (de) 2007-11-29
DE60127421T8 true DE60127421T8 (de) 2008-08-28

Family

ID=22854724

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60127421T Expired - Fee Related DE60127421T8 (de) 2000-08-25 2001-08-27 Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen

Country Status (9)

Country Link
US (1) US7364739B2 (de)
EP (1) EP1313771B1 (de)
JP (1) JP2004506086A (de)
AT (1) ATE357461T1 (de)
AU (1) AU2001285633A1 (de)
CA (1) CA2420477A1 (de)
DE (1) DE60127421T8 (de)
ES (1) ES2284681T3 (de)
WO (1) WO2002016440A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7527797B1 (en) 2000-09-01 2009-05-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae 0139 conjugate vaccines
HUP0700044A2 (en) 2004-05-14 2009-03-30 Ca Nat Research Council Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates
WO2008013735A2 (en) * 2006-07-21 2008-01-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid
JP2008125425A (ja) * 2006-11-20 2008-06-05 Osaka Univ 核酸の増幅反応に用いる繰返し配列結合プライマー及びその利用
CA2680038A1 (en) 2007-03-08 2008-09-12 The Governors Of The University Of Alberta Bacterial endotoxin for the prevention of metabolic disorders and bacterial infections
WO2016007891A1 (en) * 2014-07-10 2016-01-14 University Of Iowa Research Foundation Vaccine for nontypeable haemophilus influenzae

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3011939B2 (ja) 1987-03-02 2000-02-21 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 組換えミコバクテリア・ワクチン
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5204098A (en) * 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
ZA894589B (en) * 1989-02-09 1991-02-27 K Sudan Krishan Semi-flexible or flexible phenolic foam
JPH05504067A (ja) 1990-02-26 1993-07-01 コモンウェルス　サイエンティフィック　アンド　インダストリアル　リサーチ　オーガナイゼイション 大腸菌及びマイコバクテリアのためのシャトルプラスミド
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ATE190660T1 (de) 1990-12-18 2000-04-15 Gen Hospital Corp Verbesserte impfstoffe
CA2110682A1 (en) 1991-06-06 1992-12-10 Charles K. Stover Induction of ctl responses to foreign antigens expressed in mycobacteria
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
DE69434469T2 (de) 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US5527928A (en) * 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
DE19844191A1 (de) 1998-09-28 2000-03-30 Pharma Zentrale Gmbh Lipopolysaccharide aus Escherichia coli
DE69926261T2 (de) * 1998-12-15 2006-05-24 Exiqon A/S Koppeln an feste phasen von kohlenhydraten, die von lipopolysacchariden abgeleitet sind
EP1194567A1 (de) 1999-05-18 2002-04-10 University Of Iowa Research Foundation Produktion von komplexen kohlehydraten

Also Published As

Publication number Publication date
WO2002016440A8 (en) 2002-11-14
DE60127421D1 (de) 2007-05-03
WO2002016440A2 (en) 2002-02-28
AU2001285633A1 (en) 2002-03-04
ATE357461T1 (de) 2007-04-15
WO2002016440A3 (en) 2002-06-06
JP2004506086A (ja) 2004-02-26
EP1313771B1 (de) 2007-03-21
ES2284681T3 (es) 2007-11-16
DE60127421T2 (de) 2007-11-29
WO2002016440A9 (en) 2004-05-13
US20050153057A1 (en) 2005-07-14
EP1313771A2 (de) 2003-05-28
US7364739B2 (en) 2008-04-29
CA2420477A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
DE60238471D1 (de) Proteosom-liposaccharid-vakzine-adjuvans
NZ513840A (en) Vaccine
FI931169A0 (fi) Foerbaettrade vaccinkompositioner
MA30065B1 (fr) Vaccin
MXPA05009351A (es) Conjugados de polisacarido-proteina portadora adhesina superficial de estafilococo para inmunizacion contra infecciones nosocomiales.
TW200514569A (en) Vaccine composition
BR0015961A (pt) Antìgeno de neisseria de 85kda
MXPA05007886A (es) Vacunas para la mucosa con adyuvante de quitosan y antigenos para meningococo.
MXPA03006561A (es) Vacuna del conjugado proteina-polisacarido meningococico, multivalente.
EP1455817A4 (de) Staphylococcus aureus exopolysaccharid und verfahren
HUP0002475A2 (hu) Módosított immunogén pneumolizinkészítmények mint vakcinák
FI914564A0 (fi) Foerbaettrade konjugerade oligosackaridvacciner.
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
Farjah et al. Immunological evaluation of an alginate‐based conjugate as a vaccine candidate against Pseudomonas aeruginosa
WO2010141312A3 (en) Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
DE60127421T8 (de) Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen
ATE419873T1 (de) Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
ATE364395T1 (de) Konjugat-impfstoffe zur vorbeugung der zahnkaries
WO2001078787A3 (en) Lipopolysaccharide-conjugate vaccine for sepsis treatment

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee